210 related articles for article (PubMed ID: 12686717)
1. EMEA and Gene Therapy Medicinal Products Development in the European Union.
Papaluca Amati M; Pignatti F; Nolte A; Amerasinghe N; Gustafsson D; Moulon I; Le Courtois P
J Biomed Biotechnol; 2003; 2003(1):3-8. PubMed ID: 12686717
[TBL] [Abstract][Full Text] [Related]
2. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
3. [Europe and medicines: role of the EMEA].
Sauer F
Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
[TBL] [Abstract][Full Text] [Related]
4. [The use of nanotechnology in medicinal products in the light of European Union law].
Jurewicz M
Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
[TBL] [Abstract][Full Text] [Related]
5. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
6. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
7. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
Qu L; Zou W; Wang Y; Wang M
Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
[TBL] [Abstract][Full Text] [Related]
8. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
9. [Registration of new medicinal products in Europe].
Singer E
Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
[TBL] [Abstract][Full Text] [Related]
10. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
Vlietinck A; Pieters L; Apers S
Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
[TBL] [Abstract][Full Text] [Related]
11. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
Carr M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
[TBL] [Abstract][Full Text] [Related]
12. Marketing authorization of veterinary medicinal products in Poland.
Sztabińska-Koncka H; Lewicki J
Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
[TBL] [Abstract][Full Text] [Related]
13. The European hospital exemption clause-new option for gene therapy?
Buchholz CJ; Sanzenbacher R; Schüle S
Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
Pignatti F; Aronsson B; Vamvakas S; Wade G; Papadouli I; Papaluca M; Moulon I; Le Courtois P
Crit Rev Oncol Hematol; 2002 May; 42(2):123-35. PubMed ID: 12007970
[TBL] [Abstract][Full Text] [Related]
15. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
[TBL] [Abstract][Full Text] [Related]
16. Regulations applicable to plant food supplements and related products in the European Union.
Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
[TBL] [Abstract][Full Text] [Related]
18. [Procedure for the marketing authorization of an antibacterial agent].
López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
[TBL] [Abstract][Full Text] [Related]
19. Overview of the European regulatory approval system.
Pignatti F; Boone H; Moulon I
J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
[TBL] [Abstract][Full Text] [Related]
20. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
